TABLE 3

Relationship between early post-transplant telomere length^# and time to specified post-transplant outcomes (n=56)

	Hazard ratio	95% CI	p-value
Leukopenia requiring cessation of immunosuppression or antiviral prophylaxis medications
Telomere length^¶	1.09	0.98–1.22	0.13
Shortest telomeres⁺	1.67	0.76–3.69	0.20
Longest telomeres^§	0.60	0.24–1.50	0.27
Leukopenia requiring granulocyte colony-stimulating factor
Telomere length	1.17	1.01–1.35	0.03
Shortest telomeres	2.97	1.03–8.55	0.04
Longest telomeres	0.55	0.15–1.97	0.36
Chronic kidney disease stage 3B or higher
Telomere length	1.02	0.92–1.13	0.68
Shortest telomeres	0.61	0.24–1.54	0.30
Longest telomeres	0.86	0.37–2.02	0.74
Cytomegalovirus viraemia or end-organ damage
Telomere length	1.13	0.93–1.37	0.19
Shortest telomeres	2.43	0.70–8.41	0.16
Longest telomeres	0.45	0.09–2.13	0.32
Acute cellular rejection (any)
Telomere length	1.00	0.90–1.11	0.96
Shortest telomeres	0.75	0.31–1.83	0.54
Longest telomeres	1.15	0.50–2.64	0.74
Chronic lung allograft dysfunction-free survival (unadjusted)
Telomere length	1.24	1.07–1.44	0.004
Shortest telomeres	2.34	0.75–7.28	0.14
Longest telomeres	0.15	0.02–1.16	0.07
Chronic lung allograft dysfunction-free survival (adjusted for age, native lung disease, lung allocation score, bilateral transplant status, and acute cellular rejection score)
Telomere length	1.24	1.04–1.48	0.02
Shortest telomeres	1.79	0.50–6.43	0.37
Longest telomeres	0.08	0.007–0.944	0.04

^#: As measured within the first 100 days of transplant; ^¶: Based on the percent above or below the telomere length of the reference sample; ⁺: Defined as shortest tertile of telomere length (mean relative telomere length 0.68, overall range 0.38–0.78); ^§: Defined as longest tertile of telomere length (mean relative telomere length 1.06, overall range 0.94–1.31).